Literature DB >> 33314422

Multi-sample measurement of hyperpolarized pyruvate-to-lactate flux in melanoma cells.

Hannah Lees1,2, Micaela Millan3, Fayyaz Ahamed4, Roozbeh Eskandari1,2, Kristin L Granlund1,2, Sangmoo Jeong1,2, Kayvan R Keshari1,2.   

Abstract

Hyperpolarized [1-13 C] pyruvate can be used to examine the metabolic state of cancer cells, highlighting a key metabolic characteristic of cancer: the upregulated metabolic flux to lactate, even in the presence of oxygen (Warburg effect). Thus, the rate constant of 13 C exchange of pyruvate to lactate, kPL , can serve as a metabolic biomarker of cancer presence, aggressiveness and therapy response. Established in vitro hyperpolarized experiments dissolve the probe for each cell sample independently, an inefficient process that consumes excessive time and resources. Expanding on our previous development of a microcoil with greatly increased detection sensitivity (103 -fold) compared with traditional in vitro methods, we present a novel microcoil equipped with a 10-μL vertical reservoir and an experimental protocol utilizing deuterated dissolution buffer to measure metabolic flux in multiple mass-limited cell suspension samples using a single dissolution. This method increases efficiency and potentially reduces the methodological variability associated with hyperpolarized experiments. This technique was used to measure pyruvate-to-lactate flux in melanoma cells to assess BRAF-inhibition treatment response. There was a significant reduction of kPL in BRAFV600E cells following 24 and 48 hours of treatment with 2 μM vemurafenib (P ≤ .05). This agrees with significant changes observed in the pool sizes of extracellular lactate (P ≤ .05) and glucose (P ≤ .001) following 6 and 48 hours of treatment, respectively, and a significant reduction in cell proliferation following 72 hours of treatment (P ≤ .01). BRAF inhibition had no significant effect on the metabolic flux of BRAFWT cells. These data demonstrate a 6-8-fold increase in efficiency for the measurement of kPL in cell suspension samples compared with traditional hyperpolarized in vitro methods.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  BRAF; cancer; hyperpolarized 13C-MRS; lactate; melanoma; pyruvate

Mesh:

Substances:

Year:  2020        PMID: 33314422      PMCID: PMC8288443          DOI: 10.1002/nbm.4447

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  41 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research.

Authors:  John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

3.  Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis.

Authors:  Klaes Golman; René In't Zandt; Mathilde Lerche; Rikard Pehrson; Jan Henrik Ardenkjaer-Larsen
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

5.  Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells.

Authors:  Talia Harris; Galit Eliyahu; Lucio Frydman; Hadassa Degani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-13       Impact factor: 11.205

6.  New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.

Authors:  Anna Ferretta; Immacolata Maida; Stefania Guida; Amalia Azzariti; Letizia Porcelli; Stefania Tommasi; Paola Zanna; Tiziana Cocco; Michele Guida; Gabriella Guida
Journal:  Biochim Biophys Acta       Date:  2016-08-16

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

9.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

10.  Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.

Authors:  Stefania Acciardo; Lionel Mignion; Estelle Lacomblez; Céline Schoonjans; Nicolas Joudiou; Florian Gourgue; Caroline Bouzin; Jean-François Baurain; Bernard Gallez; Bénédicte F Jordan
Journal:  J Cell Mol Med       Date:  2019-12-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.